Vaccines are medicines that stimulate the immune system of the body
to protect against foreign substances. The stimulated immune system
destroys foreign bodies and remembers it. Vaccines work on this
principle of memorizing foreign particle and prevent infection likely to
be caused by this foreign particle when it invades again. Cancer
vaccines are medicines categorized as biological response modifiers.
These modifiers work by stimulating the immune system to fight against
disease. Broadly, cancer vaccines are of two types: prevention vaccines
and treatment vaccines. Preventive vaccines are used in healthy people
to prevent cancer. Treatment vaccines are used in cancer patients to
strengthen their natural immune response to fight the disease. Treatment
vaccine is a type of immunotherapy. Preventive vaccines are available
in the U.S. for human papillomavirus (HPV) and hepatitis B virus.
Treatment vaccine is available for metastatic prostate cancer. Cancer
preventive vaccines are more like traditional vaccines that recognize
the foreign particle and strengthen the immune system against it.
Preventive vaccines function by targeting viruses including those
producing cancer and activate the immune system against those viruses by
producing antibodies. Furthermore, cancer treatment vaccines boost
body’s natural immune system to fight against cancer cells. Cancer
treatment vaccines are provided to destroy cancer cells left in the body
following other treatments, stop further spreading of cancer, and
prevent cancer from recurring. Cancer vaccines can be administered
intravenously in children as well as adults.
The World Health Organization reported around 14 million cases of
cancer and 8.2 million cancer deaths in 2012. The most common forms
among these were lung, colorectal, prostate, cervical, and breast
cancers. Hence, demand for vaccines to prevent and treat cancers is
high.
Many clinical trials are undergoing by NCI- supported cancer prevention or treatment for different types of cancer using vaccines. Increasing cancer patients, technological advancements, drug development in the field of cancer, government support, rising geriatric population, increasing health care services and expenditure, rising awareness in the incidences of cancer, and available therapies are the factors driving the cancer vaccines market. Low availability of cancer vaccines in remote areas and the need of cold storage and transportation are the factors hampering the growth of the cancer vaccines market.
The global cancer vaccines market has been segmented based on type of
vaccine, application of vaccine, end-user, and region. In terms of type
of vaccine, the market has been categorized into antigen vaccines,
anti-idiotype vaccines, dendritic cell vaccines, whole cell vaccines,
and DNA vaccines. Based on application of vaccines, the market has been
segmented into preventive (or prophylactic) vaccines and treatment
vaccines. Preventive vaccines approved in the U.S. are HPV and hepatitis
B vaccines. Treatment vaccines can be of two types: autologous cancer
vaccines (derived from oneself) and allogenic cancer vaccines (made from
non-cancer cells of one’s own body). In terms of end-user, the cancer
vaccines market has been divided into adults and children.
Geographically, the cancer vaccines market has been segmented into
North America, Latin America, Europe, Asia Pacific, and Middle East
& Africa. North America dominates the market owing to major market
share of the U.S. However, the market in Asia Pacific is expected to
expand at the highest CAGR during the forecast period due to rising
government initiatives, increased focus of players on the vaccine
technology market in India, and rising immunization initiatives by the
World Health Organization and GAVI.
The global cancer vaccines market is dominated by key players such as AstraZeneca plc, Prima Sanofi, BioMed, GlaxoSmithKline, Merck, Aduro BioTech, OncoThyreon, and Oxford BioMedica.
Report Overview @ https://www.transparencymarketresearch.com/cancer-vaccines-market.html
Many clinical trials are undergoing by NCI- supported cancer prevention or treatment for different types of cancer using vaccines. Increasing cancer patients, technological advancements, drug development in the field of cancer, government support, rising geriatric population, increasing health care services and expenditure, rising awareness in the incidences of cancer, and available therapies are the factors driving the cancer vaccines market. Low availability of cancer vaccines in remote areas and the need of cold storage and transportation are the factors hampering the growth of the cancer vaccines market.
The global cancer vaccines market is dominated by key players such as AstraZeneca plc, Prima Sanofi, BioMed, GlaxoSmithKline, Merck, Aduro BioTech, OncoThyreon, and Oxford BioMedica.
No comments:
Post a Comment